Probiotics (multi-strain)

Preventing antibiotic-associated diarrhea (AAD) is the strongest use case. A 2019 Cochrane review of paediatric AAD (33 RCTs, ~6,352 children) found probiotics roughly halved incidence — about 8% with probiotics against 19% with placebo — with the clearest signal for high-dose L. rhamnosus GG and S. boulardii ^{3Reference 3Guo Q et al. · 2019Meta-analysisProbiotics for the prevention of pediatric antibiotic-associated diarrhea — Cochrane systematic review and meta-analysisView study →}.

The effect is real but strain-, dose- and timing-dependent: co-starting the probiotic with the antibiotic, not after, matters, and benefit is largest when baseline diarrhea risk is high. Not every trial agrees — the large adult PLACIDE trial in older UK inpatients found no reduction in AAD with its particular Lactobacillus/Bifidobacterium blend, showing that the wrong strain or population can null the effect ^{13Reference 13Allen SJ et al. · 2013RCTLactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE) — randomized controlled trialView study →}.

Gap: the effect belongs to specific proven strains at adequate CFU started promptly — a generic blend, a low dose, or a delayed start should not be assumed to work.

A 2025 Cochrane update of RCTs in adults and children found that probiotics, given alongside antibiotics, reduce the risk of C. difficile-associated diarrhea — roughly a 60% relative reduction in the pooled analysis, with moderate certainty ^{4Reference 4Esmaeilinezhad Z et al. · 2025Meta-analysisProbiotics for the prevention of Clostridioides difficile-associated diarrhea in adults and children — Cochrane systematic review and meta-analysisView study →}.

The absolute benefit tracks baseline risk: it is worthwhile where C. difficile rates are high (older inpatients, broad-spectrum antibiotics) and negligible where risk is already low. As with AAD, the benefit is tied to specific strains started early rather than to “probiotics” generically.

Gap: benefit is concentrated in high-risk settings and specific strains; PLACIDE and other trials in lower-risk or mismatched-strain populations have been null ^{13Reference 13Allen SJ et al. · 2013RCTLactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE) — randomized controlled trialView study →}.

This is one of the few life-or-death applications with strong data. A large 2023 Cochrane review — over 100 trials, more than 10,000 very preterm or very-low-birth-weight infants — found probiotics reduce severe necrotizing enterocolitis, all-cause mortality, and late-onset sepsis ^{7Reference 7Sharif S et al. · 2023Meta-analysisProbiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants — Cochrane systematic review and meta-analysisView study →}.

The effect sizes are clinically meaningful, and several neonatal units now use probiotics routinely. The major caveats are product quality and the safety of a living organism in a fragile population: pharmaceutical-grade manufacturing is essential, and rare probiotic sepsis has occurred, so this is a supervised in-hospital intervention rather than a consumer use.

Gap: strictly a clinician-supervised neonatal-unit decision using vetted products; not applicable to home use, and product-contamination and invasive-infection risks are real.

IBS is where the strain-specific message is clearest. A 2026 strain-specific systematic review with meta-analysis of placebo-controlled RCTs found that certain named strains — Bifidobacterium longum 35624, Lactobacillus rhamnosus GG, Lactiplantibacillus plantarum 299v, Saccharomyces cerevisiae CNCM I-3856, and Bacillus coagulans Unique IS2 — improved key IBS symptoms, whereas others such as Escherichia coli Nissle 1917 and Lactobacillus casei Shirota did not ^{1Reference 1Maslennikov R et al. · 2026Meta-analysisStrain-specific systematic review with meta-analysis of probiotics efficacy in the treatment of irritable bowel syndromeView study →}.

Overall symptom improvement is modest and inconsistent across products, which is exactly why the 2020 AGA guideline declined to recommend probiotics for IBS outside a trial ^{9Reference 9Su GL et al. · 2020AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders — clinical guidelineView study →}.

Gap: benefit is confined to a short list of specific strains; the category as a whole, and most shelf blends, have not shown reliable IBS efficacy.

For pouchitis — inflammation of an ileal pouch after colectomy for ulcerative colitis — a Cochrane review found that a high-dose eight-strain blend can help maintain antibiotic-induced remission and prevent onset, though the trials are small and few ^{11Reference 11Singh S et al. · 2015Systematic reviewTreatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis — Cochrane systematic reviewView study →}. This is a genuine but narrow indication used under gastroenterology care.

Gap: the evidence rests on a small number of trials of one specific high-dose multi-strain product in a niche post-surgical population; it does not generalise to ulcerative colitis or Crohn’s disease broadly.

Added to standard H. pylori triple or quadruple therapy, Saccharomyces boulardii modestly improves eradication rates and, more consistently, reduces treatment side-effects such as diarrhea — a 2019 meta-analysis with trial-sequential analysis supports the side-effect benefit and a smaller eradication gain ^{10Reference 10Zhou BG et al. · 2019Meta-analysisSaccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication — systematic review and meta-analysis with trial sequential analysisView study →}. It is an adjunct to antibiotics, never a replacement.

Gap: the reliable benefit is tolerability, not cure; the eradication improvement is small and strain-specific, mainly to S. boulardii.

A 2022 Cochrane review concluded probiotics may modestly reduce the number of people experiencing acute upper respiratory tract infections and antibiotic use, but the certainty of evidence is low and the trials are heterogeneous with possible funding bias ^{12Reference 12Zhao Y et al. · 2022Meta-analysisProbiotics for preventing acute upper respiratory tract infections — Cochrane systematic review and meta-analysisView study →}. This is the evidentiary basis behind much “immune support” marketing — and it is thin.

Gap: low-certainty evidence, a small effect, and heterogeneous strains; it does not justify strong “immune boosting” claims.

“Psychobiotic” claims are popular but poorly supported. Strain-specific meta-analyses — for example of Lactobacillus reuteri for depression — report small effects from few, small trials with high heterogeneity and short duration ^{14Reference 14Cheng Q et al. · 2025Meta-analysisThe efficacy and acceptability of Lactobacillus reuteri for the treatment of depression — systematic review and meta-analysisView study →}. Mechanistic gut–brain plausibility exists, but the human evidence is not yet strong enough to recommend probiotics as a treatment for depression or anxiety.

Gap: few small trials, high heterogeneity, and short follow-up; the gut–brain rationale is far ahead of the clinical data.

Meta-analyses consistently find that probiotic supplementation during pregnancy and infancy reduces the risk of a child developing atopic dermatitis. A 2015 meta-analysis reported an overall protective effect (OR 0.64), with the key finding that prenatal followed by postnatal administration was protective (OR 0.61) while postnatal-only administration was not ^{16Reference 16Panduru et al. · 2015Meta-analysisProbiotics and primary prevention of atopic dermatitis — meta-analysis of randomised controlled studiesView study →}.

A 2022 meta-analysis of 22 studies confirmed a reduction (RR 0.76, 95% CI 0.67–0.87), including when probiotics were given to infants alone ^{15Reference 15Chen et al. · 2022Meta-analysisProbiotics for the prevention of atopic dermatitis in infants from different geographic regions — systematic review and meta-analysisView study →}.

Gap: this is prevention of eczema, not treatment. The optimal strains, timing and duration remain uncertain, and probiotics have not shown reliable benefit for treating established atopic dermatitis.

The evidence centres almost entirely on Lactobacillus reuteri DSM 17938 in breastfed infants. Meta-analyses report meaningful reductions in daily crying — roughly 50 minutes a day averaged across strains, and about 65 minutes a day for L. reuteri DSM 17938 — with the largest effect in exclusively breastfed babies ^{17,18Reference 17Vaz SR et al. · 2024Meta-analysisProbiotics for infantile colic: is there evidence beyond doubt? — meta-analysis and systematic reviewView study →Reference 18Dos Reis Buzzo Zermiani et al. · 2021Meta-analysisEvidence of Lactobacillus reuteri to reduce colic in breastfed babies — systematic review and meta-analysisView study →}. GRADE certainty was nonetheless rated low to very low ^{18Reference 18Dos Reis Buzzo Zermiani et al. · 2021Meta-analysisEvidence of Lactobacillus reuteri to reduce colic in breastfed babies — systematic review and meta-analysisView study →}.

Gap: evidence in formula-fed and caesarean-born infants is limited and inconsistent, certainty is low, and benefit does not clearly extend to strains other than L. reuteri DSM 17938.

A network meta-analysis of 17 randomised trials found probiotics modestly reduced the incidence of travellers’ diarrhoea versus placebo (RR 0.85, 95% CI 0.76–0.95) — but that the antibiotic rifaximin was substantially more effective (RR 0.47; rifaximin versus probiotics RR 0.56) ^{19Reference 19Fan H et al. · 2022Meta-analysisProbiotics and rifaximin for the prevention of travelers’ diarrhea: A systematic review and network meta-analysis — meta-analysisView study →}.

Gap: the protective effect is small, strain-dependent, and outperformed by other prophylactic options. It is not a reliable standalone strategy for high-risk travel.